^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peripheral T-cell Lymphoma
    Drug:Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    Peripheral T-Cell Lymphomas...SUGGESTED TREATMENT REGIMENS...Other recommended regimens...Duvelisib
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Verastem Press Release
    Title:

    Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma

    Published date:
    09/06/2017
    Excerpt:
    Verastem, Inc...Duvelisib has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for the treatment of patients with PTCL who have received at least one prior therapy.